Oncology

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. […]

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both HB-201 alone and HB-202/HB-201) is highly effective at […]

AstraZeneca’s Tagrisso (osimertinib) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC) for the treatment of early-stage lung cancer.   Osimertinib will be used as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor (EGFR) exon 19 deletions or […]

Doina Ionescu, General Manager for the UK & Ireland at Merck, talks with DDW’s Megan Thomas about Merck’s innovations in the oncology sector, her thoughts on the future opportunities in the sector, as well some trade secrets and more.  MT: The company has expertise in the oncology space – what innovations can you share and can you talk me […]

Elicera Therapeutics, a Swedish clinical stage cell and gene therapy company that develops immuno-oncological treatments focusing on CAR T-cells and oncolytic viruses, has presented preclinical proof-of-concept data for the company’s iTANK-platform at the ESGCT (European Society of Gene & Cell Therapy) Virtual Congress 2021.  iTANK (immunoTherapies Activated with NAP for efficient Killing) has been developed to optimise the effect of CAR […]

This paid-for advertorial by Manchester BioGel appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Communication of cells with their microenvironment is vital in understanding intracellular processes. Most matrices lack the mechanical and biochemical tuneability necessary to recreate the cancer microenvironment. Here we discuss how PeptiGels are able […]

CN Bio has launched an oncology service which it says is in response to the global need to improve cancer drug discovery approval rates.  Understanding the relationship between pharmacokinetics, pharmacodynamics (PK/PD) and efficacy is critical to the successful development of new medicines, but at present this relationship is primarily investigated using animal models – a process that CN Bio says is time-consuming, ethically […]

Sygnature Discovery will be presenting a workshop at ELRIG UK’s Drug Discovery 2021 event entitled, Gaining a career in industry: Learning tips and tricks from the inside. It will take place on the first day of Drug Discovery 2021 in Liverpool, from 10.50 – 11.50am in Room 11B.  This workshop will be led by Allan Jordan, Director […]

Crown Bioscience has launched its ‘3D Ex Vivo Patient Tissue Platform’ which, using freshly collected patient tumour material, can accurately measure oncology and immuno-oncology drug-induced tumour killing and endogenous immune cell proliferation in a high throughput format.   Researchers presented data on the new platform at 2021’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which took place virtually on October 7-10, 2021.  […]

Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes the degradation of the WDR5 protein, […]